BioKangtai(SZ:300601)2024-04-26 11:21Financial Performance - The company's revenue for Q1 2024 was ¥451,659,438.75, a decrease of 39.65% compared to ¥748,383,301.39 in the same period last year[2]. - Net profit attributable to shareholders was ¥54,065,937.45, down 73.69% from ¥205,462,820.25 year-on-year[2]. - Basic earnings per share decreased by 72.22% to ¥0.05 from ¥0.18 in the same period last year[2]. - Total operating revenue for Q1 2024 was CNY 451,659,438.75, a decrease of 39.7% compared to CNY 748,383,301.39 in the same period last year[18]. - Net profit for Q1 2024 was CNY 54,028,967.57, a decline of 73.8% compared to CNY 205,462,820.25 in Q1 2023[19]. - Total operating costs for Q1 2024 were CNY 420,220,371.94, down 16.4% from CNY 502,644,829.28 year-over-year[18]. Cash Flow - The net cash flow from operating activities was -¥76,178,859.85, a decline of 159.24% compared to ¥128,596,484.59 in the previous year[6]. - Cash inflow from operating activities totaled CNY 551,108,624.59, a decrease of 14.2% compared to CNY 642,590,568.95 in the same period last year[22]. - The net cash flow from investing activities was -¥377,609,311.64, a decrease of 1101.60% compared to the previous year[6]. - Cash outflows from operating activities totaled 627,287,484.44 CNY, compared to 513,994,084.36 CNY in the same period last year[23]. - The net cash flow from financing activities was 122,766,816.17 CNY, a recovery from -230,650,718.67 CNY in the previous year[23]. - The company reported a total cash outflow of 331,018,835.46 CNY for the quarter[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥15,020,722,586.85, a slight decrease of 0.43% from ¥15,085,358,535.27 at the end of the previous year[2]. - Current assets decreased from RMB 5,396,003,854.07 to RMB 4,994,531,473.54, primarily due to a reduction in cash and cash equivalents from RMB 1,195,582,446.07 to RMB 876,163,610.61[14]. - The total liabilities at the end of Q1 2024 were not explicitly stated but can be inferred from the changes in current liabilities and other financial metrics[15]. - Total liabilities as of Q1 2024 were CNY 5,399,302,543.29, a decrease from CNY 5,543,673,229.15 in the previous year[19]. - Total equity attributable to shareholders of the parent company was CNY 9,621,457,013.44, an increase from CNY 9,541,685,306.12 year-over-year[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 66,057[8]. - The company reported a total of 241,737,629 restricted shares at the beginning of the period, which decreased to 235,537,028 due to the release of some shares[12]. - The number of shares held by the top 10 unrestricted shareholders includes significant holdings such as 201,730,680 shares by Yuan Liping, representing 18.1% of total shares[10]. Expenses - The company’s management expenses increased by 42.33% to ¥73,515,719.86, attributed to stock option incentives[6]. - Research and development expenses increased to CNY 107,609,673.57, up 27.4% from CNY 84,466,623.59 in the previous year[19]. - The company reported a financial expense of CNY 4,610,970.14, compared to a financial income of CNY 2,284,276.70 in the previous year[19]. Government Support and Future Plans - The company received government subsidies amounting to ¥47,169,402.03 during the reporting period, contributing to other income[3]. - The company continues to focus on R&D and market expansion strategies, although specific new products or technologies were not detailed in the report[11]. - The company plans to continue focusing on R&D and market expansion strategies to improve future performance[19]. Other Information - The company has a total of RMB 2,657,558,847.82 in other non-current assets, which increased from RMB 2,313,359,670.46[15]. - The company has not undergone an audit for the first quarter report[24]. - The company will implement new accounting standards starting in 2024[24].